

ERG addendum - Technology Assessment Report commissioned by the NIHR on behalf of the National Institute for Health and Clinical Excellence –Diagnostics Assessment Report

Title: *Testing strategies for Lynch syndrome in people with endometrial cancer*

Produced by: Warwick Evidence

Lead Author: Chris Stinton

Co-authors: Mary Jordan
Hannah Fraser
Peter Auguste
Rachel Court
Lena Alkhudairy
Jason Madan
Dimitris Grammatopoulos
Sian Taylor-Phillips

Correspondence to: Dr Sian Taylor-Phillips
Associate Professor
Division of Health Sciences
Warwick Medical School

Tel: [REDACTED]
Email: [REDACTED]

Date completed: *This addendum is current as of 25th February 2020*

Source of funding:

This report was commissioned by the NIHR Evidence Synthesis Programme as project number NIHR 129546.

Sian Taylor-Phillips is funded by an NIHR Career Development fellowship (CDF-2016-09-018).

Declared competing interests of the authors

None of the authors have any competing interests.

Acknowledgements

The authors would like to thank Professor Dimitris Grammatopoulos and Dr Mark Arends, for their expert clinical advice and to Professor Aileen Clarke and Dr Lazaros Andronis for

comments on the draft report. The authors would like to thank Kate Evans for helping with the coordinating of the report, and Sarah Abrahamson for formatting and checking the report.

Rider on responsibility for report

The views expressed in this report are those of the authors and not necessarily those of the NIHR Evidence Synthesis Programme. Any errors are the responsibility of the authors.

This report should be referenced as follows:

Testing strategies for Lynch syndrome in people with endometrial cancer. Diagnostic Assessment Report commissioned by the NIHR Evidence Synthesis Programme on behalf of the National Institute for Health and Care Excellence.

Contributions of authors

Rachel Court (Information specialist) developed the search strategy and undertook searches. Chris Stinton (Senior Research Fellow), Hannah Fraser (Research Associate), Lena Alkuhudairy (Senior Research Fellow), and James Keasley (Academic Foundation 2 doctor) conducted the clinical effectiveness systematic review, this included: screening and retrieving papers, assessing against the inclusion criteria, appraising the quality of papers and abstracting data from papers for synthesis. Chris Stinton (Senior Research Fellow) led the clinical effectiveness review. Mary Jordan (Research Fellow), Peter Auguste (Research Fellow) and Jason Madan (Professor in Health Economics) contributed to the cost-effectiveness review and undertook the health economic modelling. Dimitris Grammatopoulos (Professor of Molecular Medicine) provided clinical guidance and helped develop the model structures. Sian Taylor-Phillips (Associate Professor), led the project, and contributed to all stages for clinical and cost effectiveness. All authors were involved in writing draft and final versions of the report.

Academic and commercial in confidence information:

Please note that throughout the report academic in confidence (AIC) information is marked yellow and underlined and commercial in confidence (CIC) information is marked blue and underlined.

Net benefit per person screened with EC, deterministic vs probabilistic

Strategy	Deterministic	Probabilistic
MSI	£529	£157
MSI with MLH1 methylation	£323	£112
IHC	£570	£207
IHC with MLH1 methylation	£705	£336
MSI followed by IHC	£341	-£28
MSI followed by IHC with MLH1 methylation	£124	-£99
IHC followed by MSI	£344	-£18
IHC followed by MSI with MLH1 methylation	£475	£104
MSI and IHC simultaneously	£302	-£71